Announces agreements with Nippon Kayaku, Takara Shuzo and the Institute of Microbial Chemistry to develop deoxyspergualin, a potential anticancer and immunosuppressive agent. Phase II trials with deoxyspergualin are underway at NCI and clinical trials for kidney transplantation and autoimmune disease are planned in Japan. Hoechst is conducting trials in Europe. Scientific papers on the drug were presented at the 12th International Congress of the Transplantation Society in Sydney, Australia.
You may also be interested in...
A trio of newly finalized guidance documents from the US agency dated 25 September explain how the Accreditation Scheme for Conformity Assessment pilot will work, and what biocompatibility and safety standards will apply.
Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals.
Unfounded expectation some firms have for FDA to protect their investments in preparing successful NDI notifications is part of industry’s overall interest in increased regulation of the market, says Steven Tave, Office of Dietary Supplement Programs director.